Sign up
Pharma Capital

Uscom Ltd to develop digital spirometry devices with European grant

The company’s technology is being trialled in the U.S., Spain and France.
Uscom’s solution provides cloud based analysis and diagnosis

Uscom Ltd (ASX:UCM) has been awarded an additional European scientific research grant to fund the research and development of new digital pulmonary disease management technologies.

This second stage of the grant, for a further $330,000, takes the Uscom Europe grant total for this project to $820,000 over the next two years.

The funds have been granted to develop new digital spirometry devices and software under the Eurostars program and will be paid on achieving development milestones.

The total grant value to the consortium for the project is €2.07 million (circa $3.09 million).

Uscom’s digital multi-path ultrasonic technology is already being adopted in cloud based telemetric pulmonary monitoring projects in the U.S., Spain and France.

The company’s SpiroReporter archiving and analysis software can be installed on smartphones, tablets, computers or the cloud.

The software has the ability to combine complex pulmonary function measurements with a remote digital monitoring platform, adding clinical utility to Uscom’s devices.

While many companies offer inhaler trackers connected to an app, the SpiroSonic solution provides cloud based analysis, diagnosis and management, generating “big data” for population disease profiling.

As air quality deteriorates and lung disease increases, these initiatives are becoming increasingly important for global health.

This funding is expected to result in new Uscom devices and digital solutions to improve asthma and chronic obstructive pulmonary disease (COPD) worldwide.

Register here to be notified of future UCM Company articles
View full UCM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.